Clinical Research Directory

Browse clinical research sites, groups, and studies.

1 clinical study listed.

Healthy volunteers

Filters:

Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Tundra lists 1 Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia clinical trial. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07523555

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Phase 1/2 umbrella study evaluates biomarker-selected dual-target CAR-T cell modules for adults with relapsed or refractory hematologic malignancies. After central antigen co-expression screening, participants are assigned to the most appropriate active dual-target module: CD19/CD22, CD19/CD20, BCMA/CD19, BCMA/CD38, BCMA/GPRC5D, CD33/CD123, CD33/CLL1, or CD5/CD7. Phase 1 determines safety, dose-limiting toxicities, and the recommended phase 2 dose for each module; phase 2 estimates preliminary antitumor activity, including overall response rate and MRD-negative response. Lymphodepletion with fludarabine/cyclophosphamide precedes infusion. The design is intended to reduce antigen escape by matching disease biology and target co-expression to a rational dual-target strategy.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2026-04-13

1 state

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL

Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia